This study is testing a new drug called DFP-14927 for people with advanced solid tumors (cancers that form in solid organs like the breast or lung) that have not responded to standard treatments or for which no effective treatment is available. DFP-14927 works by targeting the immune system. The main goals are to find the highest safe dose of DFP-14927, understand its side effects, and determine the recommended dose for future studies. You can join if you are 18 or older and have a confirmed solid tumor diagnosis. This study is currently recruiting about 30 participants.

Study design

This is a Phase I, open-label (meaning you and your doctors will know what treatment you are receiving), single-arm study, meaning all participants receive the same treatment. It aims to enroll about 30 participants.

What's involved

You would receive DFP-14927 as an intravenous (IV) infusion weekly for each 28-day cycle. The study will observe drug-related toxicities and dose-limiting toxicities.

Compensation

Not stated in the trial record.

Follow-up

You will be followed from your first dose up to 30 days after your last dose to assess safety and side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.